Apogee Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Apogee Therapeutics, Inc. | APGE - NASDAQ |
$15.00-$17.00 | $17.00 | $21.50 | 17.7 million | 7/14/2023 |
| Jefferies, TD Cowen, Stifel, Guggenheim Securities | ||||||
Co-Manager(s): Wedbush | ||||||
| Health Care | ||||||
Filing(s): Filed 2023-06-22 Terms Added 2023-07-10 | ||||||
Apogee Therapeutics, Inc. Quote & Chart - Click for current quote - APGE
IPO Boutique aggregates information on public companies and private companies, such as "APGE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Apogee Therapeutics, Inc. (adapted from Apogee Therapeutics, Inc. prospectus):
They are a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "APGE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.